About Seres Therapeutics
Seres Therapeutics (NASDAQ:MCRB) is a biotechnology company focused on transforming the lives of patients by targeting the microbiome to treat disease and improve human health. It is at the forefront of microbiome therapeutics, advancing a novel class of biological drugs. Seres is engaged in developing a portfolio of product candidates designed to restore the natural ecology of the human microbiome for patients affected by serious diseases. Their projects include therapies for conditions such as Clostridioides difficile infection, ulcerative colitis, and others within the gastrointestinal disease area. The company's objective is to lead in microbiome therapeutics by advancing science and exploring new treatment modalities for a range of diseases linked to the dysfunction of the microbiome.
Snapshot
Operations
Products and/or services of Seres Therapeutics
- SER-109, an oral microbiome therapeutic for reducing recurrent Clostridioides difficile infection (CDI).
- SER-287, an oral microbiome treatment for active mild-to-moderate ulcerative colitis.
- SER-401, a microbiome therapeutic for improving outcomes in melanoma patients undergoing immunotherapy.
- SER-301, an engineered microbiome therapeutic for inflammatory bowel disease.
- SER-262, the first synthetically derived microbiome therapeutic aimed at preventing CDI recurrence.
- Collaborative research projects with leading pharmaceutical companies to develop microbiome-based therapies for various indications.
Seres Therapeutics executive team
- Mr. Thomas J. DesRosier Esq., J.D.Co-CEO, Co-President & Chief Legal Officer
- Ms. Marella Thorell CPACo-CEO, Co-President & CFO
- Dr. Matthew R. Henn Ph.D.Executive VP & Chief Scientific Officer
- Dr. Teresa L. Young Ph.D., R.Ph.Executive VP and Chief Commercial & Strategy Officer
- Mr. Chris McChalicherSenior VP of Manufacturing, Quality, and Process Development
- Dr. Dennis M. Walling M.D.Senior VP of Clinical Development & Head of Clinical Research
- Ms. Ann KurowskiSenior Vice President of Regulatory Affairs
- Ms. Kelly BradySenior Vice President of Clinical Development
- Ms. Caroline HensleyAssistant General Counsel